XBiotech Q2 FY26 net loss widens to $6.73 million; no revenue

Reuters2026/08/13 15:27

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

XBiotech posted a GAAP net loss of USD 6.73 million for the quarter ended June 30, 2026, widening from USD 1.76 million.
Loss per share widened to USD 0.22 from USD 0.06.
Operating loss widened to USD 6.15 million from USD 6.34 million.
Research and development expense edged down 1% to USD 5.3 million; general and administrative expense fell 15% to USD 850,000.
Cash and cash equivalents totaled USD 109.53 million at June 30, 2026, down from USD 125.55 million at Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XBiotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005492), on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

XBiotech Q2 FY26 net loss widens to $6.73 million; no revenue

You may also like

Crypto prices